GSK, Spero ink licence agreement for tebipenem HBr, a late-stage antibiotic that may treat complicated urinary tract infections

GSK plc and Spero Therapeutics, Inc. announced they have entered into an exclusive licence agreement for tebipenem pivoxil hydrobromide (tebipenem HBr), a late?stage antibiotic being developed by Spero, as the